Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rivaroxaban + acetylsalicylic acid + clopidogrel
- Development stage
- Phase 4
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination antithrombotic therapy consisting of rivaroxaban (a direct factor Xa inhibitor), acetylsalicylic acid (an antiplatelet agent that inhibits cyclooxygenase-1), and clopidogrel (a P2Y12 receptor antagonist). This triple therapy provides enhanced cardiovascular protection but significantly increases bleeding risk compared to single or dual therapy regimens.
- Other names
- triple therapytriple antithrombotic therapy
02
Targets
F10 (Factor Xa)PGHS-1 (Prostaglandin G/H Synthase 1)P2Y12 (Purinergic P2Y12 receptor)
Beyond the preview
Go deeper on rivaroxaban + acetylsalicylic acid + clopidogrel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rivaroxaban + acetylsalicylic acid + clopidogrel.